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Revertant mosaicism by somatic reversion of inherited mutations has been described for a number of genetic diseases.
Several mechanisms can underlie this reversion process, such as gene conversion, crossing-over, true back mutation,
and second-site mutation. Here, we report the occurrence of multiple corrections in two unrelated probands with
revertant mosaicism of non-Herlitz junctional epidermolysis bullosa, an autosomal recessive genodermatosis due
to mutations in the COL17A1 gene. Immunoﬂuorescence microscopy and laser dissection microscopy, followed by
DNA and RNA analysis, were performed on skin biopsy specimens. In patient 1, a true back mutation, 3781TrC,
was identiﬁed in the specimen from the arm, and a second-site mutation, 4463-1GrA, which compensated for the
frameshift caused by the inherited 4424-5insC mutation, was identiﬁed in the 3′ splice site of exon 55 in a specimen
from the middle ﬁnger. Patient 2 showed—besides two distinct gene conversion events in specimens from the arm
and hand sites, both of which corrected the 1706delA mutation—a second-site mutation (3782GrC) in an ankle
specimen, which prevented the premature ending of the protein by the 3781CrT nonsense mutation (R1226X).
Thus, both inherited mutations, paternal as well as maternal, reverted at least once by different reversion events
in distinct cell clusters in the described patients. The occurrence of multiple correcting mutations within the same
patient indicates that in vivo reversion is less unusual than was generally thought. Furthermore, in the male patient,
mosaic patterns of type XVII collagen–positive keratinocytes were present in clinically unaffected and affected skin.
This latter observation makes it likely that reversion may be overlooked and may happen more often than expected.
Introduction
Genetic mosaicism is deﬁned as the presence of two or
more genetically distinct populations of cells that differ
from each other in their DNA but are derived from a
single zygote within one individual (Hall 1988). If an
inherited disease-causing mutation is corrected in a so-
matic cell by means of a second genetic event, gene func-
tion can be completely or partially restored in these so-
called revertant cells. Correction of a stem cell will lead,
in this case, to life-long repair. This phenomenon of “nat-
ural gene therapy” has led to revertant mosaicism in
several human inherited diseases, including epidermo-
lysis bullosa (EB), tyrosinemia type I (MIM 276700),
Bloom syndrome (MIM 210900), Fanconi anemia (FA
[MIM 227650]), and primary immunodeﬁciency syn-
dromes, such as Wiskott-Aldrich syndrome (WAS [MIM
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301000]), X-linked severe combined immunodeﬁciency
(X-linked SCID [MIM 300400]), and adenosine deam-
inase deﬁciency (MIM 102700) (for reviews, see Hirsch-
horn [2003] and Jonkman et al. [2003]). Restoration of
gene function is obtained by different genetic mecha-
nisms, including back mutation, intragenic crossover,
mitotic gene conversion, and second-site mutation (Kvit-
tingen et al. 1994; Ellis et al. 1995; Jonkman et al. 1997).
Among the reported second-site mutations are a reading-
frame–restoring insert of 2 bp and a frameshift mutation
that nulliﬁes a dominant-negative allele (Darling et al.
1999; Smith et al. 2004). Despite this apparent range of
reversion mechanisms available to the human body, only
a single type has been found in each individual patient,
apart from one very recently described individual with
tyrosinemia type I (Bliksrud et al. 2005). This suggests
either that such in vivo reversion is a one-time single
event or that a particular mechanism is preferred for
correction of a speciﬁc type of mutation.
Generalized atrophic benign epidermolysis bullosa
(GABEB [MIM 226650])—which is the generalized var-
iant of non-Herlitz junctional epidermolysis bullosa
(nH-JEB), an autosomal recessive bullous genoderma-
tosis—is characterized by generalized skin blistering
from birth onward, dental anomalies, universal alope-
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cia, and nail dystrophy (Hintner and Wolff 1982; Jonk-
man et al. 1996). The underlying defect is mutation of
the COL17A1 gene, which encodes the 180-kDa type
XVII collagen (Jonkman et al. 1995; McGrath et al.
1995) (human COL17A1 mRNA sequence: GenBank
accession number NM_000494; human COL17A1 tran-
script sequence: GenBank accession numberNP_000485).
The COL17A1 gene spans 52 kb of the genome on
chromosome 10 and encompasses 56 exons that range
in size from 27 to 390 bp (Li et al. 1991; Gatalica et
al. 1997). Type XVII collagen is a glycosylated type II
transmembrane protein of 1,497 aa. Its COOH-termi-
nal extracellular part, comprising approximately two-
thirds of the protein, contains 15 interrupted collage-
nous domains, designated “COL1”–“COL15” (Li et al.
1993). The protein is expressed in basal epithelial cells
and is part of the hemidesmosome, a critical structure
for attachment of basal epithelial cells to the underlying
matrix. Although type XVII collagen almost certainly
has signal-transduction properties, its main function is
to act as a transmembrane link in the molecular chains
that anchor the cytoskeleton of the basal keratinocytes
to the basement membrane.
Previously, we demonstrated that the in vivo reversion
in keratinocytes cultured from a revertant skin patch of
the hand of a patient with GABEB was the result of
mitotic gene conversion, the nonreciprocal transfer from
one chromosome to another (Jonkman et al. 1997).
Here, we expand these studies by analyzing separate
revertant patches within individual patients. Using laser
dissection microscopy (LDM), we now ﬁnd that differ-
ent correcting COL17A1 mutations are responsible for
the restoration of type XVII collagen expression in dis-
tinct cell clusters within the same patient.
Material and Methods
Biopsy Sites
For immunoﬂuorescence (IF) microscopy, six 4-mm
punch-biopsy specimens were obtained and were snap
frozen: two from clinically unaffected skin of the right
middle ﬁnger of a 75-year-old man (patient 1), three
from nonlesional affected skin of his right upper arm,
and one from nonlesional affected skin of his shoulder.
Biopsy specimens from unaffected skin of the left fore-
arm and the right upper arm of a 45-year-old woman
(patient 2) were also analyzed. In addition to specimens
from these biopsy locations described by Jonkman et al.
(1997), another biopsy specimen was obtained from un-
affected skin of the left ankle.
For electron microscopy, three 2-mm punch-biopsy
specimens were obtained from patient 1: two from le-
sional affected skin of the right upper arm and one from
unaffected skin of the right middle ﬁnger.
Immunomorphological Analysis of Skin and Cultured
Keratinocytes
Details of IF microscopy, electron microscopy, and
keratinocyte culturing have been described extensively
elsewhere (Jonkman et al. 1995). For detection of type
XVII collagen, the following monoclonal antibodies
were used: 1A8C, speciﬁc to the endodomain (epitope
located between amino acids 155 and 160), and 1D1
and 233, both speciﬁc to the ectodomain (1D1 epitope
located between amino acids 1357 and 1387; 233 epi-
tope located between amino acids 1118 and 1143) (all
were gifts from Dr. K. Owaribe [Nagoya, Japan]) (Di
Zenzo et al. 2004). The Alexa488-conjugated goat anti-
mouse IgG antibody (Brunschwig Molecular Probes)
was used for a secondary step.
Mutation Detection Strategy
The detection of mutations in the genomic DNA of
patient 2 has been published previously (Jonkman et al.
1997). For identiﬁcation of the mutations in the DNA
of patient 1, all 56 exons of COL17A1 were ampliﬁed
using the primers described by Gatalica et al. (1997) and
subsequently sequenced (GenBank accession numbers
U76564–U76604), except the primer for exon 46. For
exon 46, we used instead the sense primer 5′-GTGCTT-
CAGGTCACCTCCGT-3′ and the antisense primer 5′-
ACGAGGAGATGAGGCTCTGG-3′. Unfortunately, ge-
nomic DNA from the parents or from other ﬁrst-degree
relatives of patient 1 was no longer available.
Veriﬁcation of Mutations
Veriﬁcation of the 1706delA mutation in exon 18 and
the 3781CrT mutation in exon 51 by restriction anal-
ysis was done as described elsewhere (Jonkman et al.
1997). The 4424-5insC mutation in exon 54 does not
create or abolish a restriction site and was therefore ver-
iﬁed by repeated sequencing.
LDM
For DNA recovery by LDM, skin cryosections of 4
mm were mounted on 1.35-mm-thin polyethylene-naph-
thalene membranes attached to normal 1-mm slides and
were stained with monoclonal antibody 1D1 by use of
the same staining procedure described elsewhere (Jonk-
man et al. 1997), except for the absence of the bisben-
zimid step in the protocol. For selection of the sites of
epidermal basement membrane that stained either pos-
itive or negative for type XVII collagen, IF images were
acquired using a digital camera and were processed with
P.A.L.M. RoboSoftware 1.2 (P.A.L.M. Microlaser Tech-
nology AG). Cells were dissected using the Laser Robot
Microbeam System (P.A.L.M. Microlaser Technology
AG). Dissected areas were directly collected in the cap
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Table 1
PCR Ampliﬁcation of COL17A1 Genomic DNA
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 2
PCR Ampliﬁcation of COL17A1 cDNA
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
of a 0.2-ml thin-wall reaction tube with a ﬂat cap con-
taining 30 ml of one-time PCR buffer (Amersham Phar-
macia Biotech) and 1 ml of proteinase K (Invitrogen).
For RNA recovery, staining with monoclonal antibody
1D1 was omitted because we noted that, after stain-
ing, almost all the RNA was lost. Therefore, serial cryo-
sections were prepared, and every fourth section was
mapped by IF microscopy. On the basis of the staining
pattern of these sections, the epidermis of ﬁve to sev-
en skin sections was collected in the cap of a 0.5-ml
P.A.L.M. tube (P.A.L.M. Microlaser Technology) that
contained 30 ml of lysis buffer (Stratagene Europe) and
was used for RNA isolation.
DNA Isolation of LDM Samples
Microdissected epidermis from ∼200 cells was col-
lected in a 0.2-ml reaction tube. During digestion by
proteinase K, the tubes remained inverted for 60 min at
55C; subsequent heating to 98C for 15 min inactivated
the proteinase K. The ﬁnal aliquots were used for PCR.
Cytospin
To analyze DNA of cultured revertant keratinocytes
from the hand of patient 2, cytospin was conducted;
1.35-mm-thin polyethylene-naphthalene membranes at-
tached to normal 1-mm slides (P.A.L.M. Microlaser
Technology AG) were coated with 10 ml of polylysine
and were dried for 30 min at 37C. Cytospin was per-
formed with a number of cells sufﬁcient to allow LDM
isolation of reverted cells. The glass slides were then
dried. Subsequently, the cells were ﬁxed for 10 min at
room temperature by use of 1% formaldehyde in phos-
phate-buffered saline, were washed, and were incubated
for 5 min in 0.5% Triton X-100 in phosphate-buffered
saline. The cells were stained with monoclonal 1A8C,
as described elsewhere (Jonkman et al. 1995), and were
then used for LDM.
RNA Isolation
Tubes were centrifuged for 1 min at 10,000 g, and 70
ml of lysis buffer containing 0.7 ml of b-mercaptoethanol
was added. Total RNA was then prepared using the
Stratagene RNA nanoprep kit (Stratagene), for a ﬁnal
volume of 10 ml.
cDNA Synthesis
For cDNA synthesis, 1 ml of 300-ng/ml random prim-
ers (Invitrogen) and 1 ml of 10 mM dNTP mix (Fer-
mentas) were added to 10 ml of total RNA and were
incubated for 5 min at 65C. The tubes were then im-
mediately put on ice, and 5 ml of 5# First Strand buffer,
2 ml of 0.1 M dithiothreitol, and 1 ml of 10-units/ml
RNase Inhibitor Cloned (all Invitrogen) were added. In-
cubation for 10 min at 25C was followed by 2 min at
42C. Finally, 1 ml of 1-unit/ml Superscript II RNase H
Reverse Transcriptase (Invitrogen) was added. Tubes
were incubated for 50 min at 42C, followed by 15 min
at 70C to inactivate the enzyme. For PCR, 10 ml of
cDNA was used in a total volume of 50 ml.
Identiﬁcation of Mutations in LDM Samples
For detection of mutations in LDM-isolated DNA, we
used nested PCR. For the second PCR, 1 ml of the ﬁrst
PCR product was used. PCR cycling conditions were 5
min at 94C, followed by 30 cycles at 94C for 45 s,
55C for 45 s, and 72C for 1 min and 30 s and a ﬁnal
extension at 72C for 7 min. Water, instead of DNA,
was used as a negative control. Primer sequences and
sizes of PCR products are listed in table 1. After PCR,
aliquots of 14 ml were examined using 4% agarose gel
electrophoresis.
Also, the cDNA samples from dissected cells were sub-
jected to nested PCR. All primers were designed in such
a way that the PCR product contained sequences from
multiple exons. Primer sequences for ampliﬁcation of
COL17A1 cDNA and sizes of PCR products are listed
in table 2. All PCRs were repeated with templates from
at least three separate nucleic-acid isolations obtained
by LDM, and all products were sequenced.
Identiﬁcation of SNPs in LDM Samples
For the identiﬁcation of SNPs, nested PCRs and, in a
few cases, seminested PCRs were performed. Primer se-
quences and sizes of PCR products for 182214T/C in
intron 19 (dbSNP identiﬁer rs17821926), 2268120T/
C in intron 28 (Gatalica et al. 1997), 2700T/C in exon
37 (rs4918079), 2988A/C in exon 43 (rs2296219), and
4214A/G in exon 52 (rs17116350) are listed in table 1.
Like the identiﬁcation of the mutations in LDM samples,
all PCRs for SNPs were repeated with templates from
at least three separate nucleic-acid isolations obtained
by LDM, and products were sequenced afterward.
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Figure 1 Clinical and cellular mosaicism in the skin of patient
1. A, Patch of skin on the right hand where blisters had never occurred
(circled). A biopsy specimen was obtained from the middle of this
unaffected area. B, IF staining of type XVII collagen with monoclonal
antibody 1D1 in human healthy control skin. C, Mosaic pattern along
the dermal-epidermal junction of type XVII collagen stained with
monoclonal antibody 1D1, observed in the right middle ﬁnger.D,Basal
cells that stained positive for type XVII collagen, observed in the right
upper arm despite the affected skin of the upper arm.
Microsatellite Analysis
To detect possible crossovers in the DNA of patient
2, the alleles ﬂanking the COL17A1 gene on chromo-
some 10q24.3 were analyzed using microsatellite poly-
morphisms (Gyapay et al. 1994). The ﬂanking mar-
kers D10S603 and D10S597 (8 cM apart) were used.
D10S566 and D10S554 were not analyzed, since these
were homozygous in the patient’s DNA and were thus
not informative (Jonkman et al. 1997). For analysis of
the microsatellitesD10S603 andD10S597,we also used
nested PCRs, because of the small amount of LDM-
isolated DNA. Primers for the ﬁrst PCR for D10S603
were sense primer 5′-GCTGGATTATCTCGGTAACC-
3′ and antisense primer 5′-GTTCATCTCCCAAGGCA-
ATG-3′. Primers for the ﬁrst PCR for D10S597 were
sense primer 5′-AGAAGAGGAAGGCTGTCAGA-3′ and
antisense primer 5′-GCCACAAGACTTGTGTTTGC-3′.
Primers for the second PCRs were as described elsewhere
(Gyapay et al. 1994).
Cloning
The nested PCR product of exon 51 from the ankle
specimen of patient 2 was cloned into the pCR4-TOPO
(Invitrogen) vector to investigate whether the mutations
3781CrT and 3782GrC were located on the same
chromosome. Five clones were selected and sequenced.
Results
Patient 1
The ﬁrst proband was a 75-year-old Dutch male who
had the GABEB variant of nH-JEB. Since birth, he had
generalized blistering after minor trauma, without evi-
dence of scarring or milia formation. He also had uni-
versal alopecia, small rudimentary nails, and enamel hy-
poplasia. His nonconsanguineous parents and his sister
were healthy. On clinical examination, he presentedwith
a circular patch of clinically unaffected skin, ∼2 cm2 on
his right middle ﬁnger, which tolerated the wearing of
his wedding ring (ﬁg. 1A). This skin looked perfectly
healthy and sturdy, and no blisters had ever occurred
there. The size of this unaffected area had remained sta-
ble throughout his life. This clinical presentation was
suggestive of revertant mosaicism, since the nH-JEB
symptoms were generalized, with the rare exception of
the patch on the middle ﬁnger. Two biopsy specimens
of the unaffected skin of the right middle ﬁnger, three
of the nonlesional affected skin of the right upper arm,
and one of the lesional affected skin of the shoulder were
studied using IF microscopy. Staining with monoclonal
antibodies against type XVII collagen showed a mosaic
pattern in both biopsy specimens of the middle ﬁnger.
The epidermal basement membrane stained positive for
type XVII collagen, showing the same intensity as nor-
mal human control skin, with one interruption of ∼150
mm that was not stained, which resembled 10% of the
basal cells of this biopsy specimen (ﬁg. 1B and 1C). In
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Figure 2 Electron microscopy of affected and revertant skin of patient 1. A and C, Affected skin of the arm, showing basal keratinocytes
with intermediate ﬁlaments that do not project to the ﬂattened basilar cell periphery, which almost completely lacks hemidesmosomes. B and
D, Revertant skin of the middle ﬁnger, revealing pronounced rootlets of basal keratinocytes containing intermediate ﬁlaments that connect to
normal hemidesmosomes in the basilar cell periphery. In keratin, white arrows indicate intermediate ﬁlaments, large black arrows indicate
hemidesmosomes, and small black arrows indicate the lamina densa. Calibration bars represent 2 mm in panels A and B and 500 nm in panels
C and D.
contrast, the specimen from the nonlesional affected skin
of the shoulder and two specimens from the upper arm
were completely negative for type XVII collagen. How-
ever, the third upper-arm biopsy specimen of affected
skin demonstrated an interruption in the dermal-epi-
dermal junction: ∼500 mm (25% of the basal cells) of
type XVII collagen–expressing cells (ﬁg. 1D).
Electron microscopy of gently rubbed affected skin
showed a cleavage plane through the lamina lucida,
thereby conﬁrming the JEB diagnosis (data not shown).
In nonlesional affected skin, hemidesmosomes were low
in number (!5 per 40 mm of basement membrane vs.
49–98 per 40 mm in normal control skin) and appeared
to be hypoplastic (ﬁg. 2A and 2C). The unaffected skin
of the middle ﬁnger showed a larger number of hemi-
desmosomes (41 per 40 mm) than the affected skin (ﬁg.
2B and 2D), and these hemidesmosomes were normal
in shape.
To determine mutations in COL17A1, DNA was iso-
lated from peripheral blood lymphocytes and was se-
quenced with intron primers (Gatalica et al. 1997). Two
heterozygous mutations were identiﬁed: a nonsense mu-
tation in exon 51, 3781CrT (R1226X), and an insertion
of a C in exon 54 between nucleotides 4424 and 4425.
This insC mutation caused a frameshift, resulting in a
novel sequence beginning at amino acid 1441 and lead-
ing to a premature termination codon (PTC) at position
1453.
To study the cells re-expressing type XVII collagen in
the mosaic biopsy specimens, we needed a technique that
could isolate separately the different cell populations:
type XVII collagen–negative keratinocytes and type
XVII collagen–positive keratinocytes. LDM allows for
recovery of DNA and RNAdirectly frombiopsymaterial
and eliminates the necessity of culturing the keratino-
cytes with the risk of selection in vitro. Furthermore, in
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Figure 3 Identiﬁcation of the different correcting COL17A1 mutations. A, Nonsense mutation 3781CrT in exon 51 and insertion 4424-
5insC in exon 54, present in keratinocytes of patient 1 that stained negative for type XVII collagen. Note that exon 54 was sequenced with a
reverse primer to circumvent the problem of the double sequence due to the insertion. B, Additional mutation in the 3′ splice site of exon 55,
4463-1GrA, in keratinocytes of the middle ﬁnger that stained positive. C, Absence of the exon 51 nonsense mutation (3781CrT) in keratinocytes
of the upper arm that stained positive. D, Inherited mutations 1706delA in exon 18 and 3781CrT in exon 51, present in keratinocytes of
patient 2 that stained negative. E, Additional mutation 3782GrC in keratinocytes of the ankle that stained positive. F, Absence of the exon
18 deletion (1706delA) in keratinocytes of the forearm and upper arm that stained positive. Red arrows indicate the position of the mutations,
and green arrows indicate the second-site mutations.
vivo spliced mRNA is analyzed, which excludes possible
deviant splicing due to culturing conditions, as was dem-
onstrated for the hemidesmosomal protein integrina6b4
(Chavanas et al. 1999).
Interestingly, the type XVII collagen–positive cells of
the middle ﬁnger, isolated by LDM, carried an additional
mutation, 4463-1GrA, in the intron 54–exon 55 border,
on the same allele as the 4424-5insC mutation (ﬁg. 3B).
This second-site mutation changes the consensus se-
quence of the 3′ splice site, which ends with the invariant
AG. In this case, the invariant G is replaced with an A,
and, since exon 55 starts with a G, a possible new splice
site is created 1 nt further downstream. Subsequently,
RNA was isolated from epidermis that stained posi-
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Figure 4 Effects of the second-site mutations on mRNA. A, Ad-
ditional mutation 4463-1GrA, which results in an mRNA transcript
with a deletion of 1 nt, 4463delG. B, Nucleotides 4459–4467 of
mRNA of normal human skin, which served as a control. C, Com-
pensatory mutation 3782GrC, which changes the PTC caused by the
3781CrT mutation into the amino acid serine. D, Nucleotides 3778–
3786 of mRNA of normal human skin, which served as a control.
Red arrows indicate the position of the mutations, and green arrows
indicate the second-site mutations.
tive, and this RNA indeed showed a deletion of G at
position 4463 (ﬁg. 4A and 4B). This deletion restores the
frameshift caused by the 4424-5insC mutation, begin-
ning at amino acid 1453, and results in a protein of
correct size but with a stretch of 13 different amino
acids (GQKGEMGTPGPKGrWAKRRDGHSRTQS) in
the ﬁrst collagenous domain (COL1). Since the patient’s
middle ﬁnger displays healthy skin, this protein is func-
tional enough to restore normal skin strength,which also
implies that, despite the disruption of the Gly-X-Y col-
lagen motif, the changed amino acids are not essential
for interactions with other hemidesmosomal proteins.
Unexpectedly, the analysis of the revertant cells of the
upper arm showed something completely different. The
frameshift caused by the 4424-5insC mutation was not
corrected, because the restoring mutation 4463-1GrA
was lacking. However, the 3781CrT mutation on the
other allele was missing, thus revealing another reversion
mechanism in these keratinocytes (ﬁg. 3C). The absence
of this nonsense mutation in exon 51, in combination
with the presence of immunoreactive type XVII collagen,
could be caused by various genetic mechanisms: gene
conversion, single crossing-over, or true back mutation.
These mechanisms can result in somatic cells becoming
homozygous at loci during mitotic recombination. To
differentiate between these possibilities, SNPs around
the exon 51 mutation in the COL17A1 gene were in-
vestigated for loss of heterozygosity in revertant kera-
tinocytes of the upper arm (table 3) (Gatalica et al. 1997;
Jonkman et al. 1997). A true back mutation would only
revert the nonsense mutation, leaving the SNPs in intron
28 (2268120T/C) and exon 52 (4214A/G) unaffected.
In contrast, single crossing-over and gene conversion
would result in loss of heterozygosity of one or both
SNPs surrounding exon 51. Since the SNPs in intron 28
and exon 52 were found to be still heterozygous, a single
crossing-over can be excluded as the genetic mechanism.
The heterozygosity of the SNPs in intron 28 and exon
52 indicates instead that true back mutation (3781TrC)
is the underlying mechanism. Nevertheless, we cannot
completely rule out gene conversion, because this can
occur even when limited to tens of nucleotides (Smithies
and Powers 1986).
Patient 2
The second proband, a 45-year-old female with re-
vertant mosaicism, who is compound heterozygous for
a paternal mutation in exon 51, 3781CrT (the same
mutation as in patient 1), and who has a maternal dele-
tion in exon 18, 1706delA, has been described elsewhere
(Jonkman et al. 1997). She had unaffected nonconsan-
guineous parents and the same constellation of symp-
toms as patient 1, which classiﬁed her condition too as
the GABEB variant of JEB. About 10% of her total body
surface was covered with revertant skin. Extensive photo
documentation from 1994 and 2005 showed the sta-
bility of the patches and excluded the possibility of ex-
pansion of the clinically unaffected skin (ﬁg. 5A–5F).
We demonstrated elsewhere that, in cultured revertant
keratinocytes derived from the dorsum of the patient’s
left hand, a gene conversion had occurred, resulting in
the loss of the maternal deletion (Jonkman et al. 1997).
For the current study, with the intriguing results of pa-
tient 1 in mind and with the possibility of directly an-
alyzing stored skin-biopsy specimens by use of the LDM
technique, we reinvestigated this patient. Besides the
patches of unaffected skin on her arms and hands, the
patient indicated another unaffected patch on the ankle,
which is also visible in photographs taken in 1969. IF
microscopy showed that, in the ankle specimen, in con-
trast to the interrupted pattern in the biopsy specimens
of the forearm and the right upper arm (50% of cells
positive for type XVII collagen), the whole epidermal
basement membrane stained positive for type XVII col-
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Table 3
Inherited and Somatic Mutations in the COL17A1 Gene
PATIENT AND
SNPS IN
EXON OR INTRON
OF COL17A1
NUCLEOTIDE
POSITION Blood
Upper
Arm
Middle
Finger Forearm Ankle Handa
Patient 1:
Intron 19 182214 T C T C T C … … … … … …
Intron 28 2268120 T C T C T C … … … … … …
Exon 51 3781 C T C C C T … … … … … …
Exon 52 4214 G A G A G A … … … … … …
Exon 54 4424–4425 insC … insC … insC … … … … … … …
Intron 54 4463-1 G G G G A G … … … … … …
Patient 2:
Exon 18 1706 A del A A … … A A A del A A
Intron 19 182214 C T C C … … C C C T C T
Intron 28 2268120 C T C T … … C T C T C T
Exon 37 2700 T C T C … … T C T C T C
Exon 43 2988 A C A C … … A C A C A C
Exon 51 3781 T C T C … … T C T C T C
Exon 51 3782 G G G G … … G G C G G G
NOTE.—SNPs within the COL17A1 gene are indicated by nucleotides. The pathogenic mutations are underlined, and
the compensatory second-site mutations are in bold italics.
a Data for the hand were obtained from Jonkman et al. (1997).
lagen, with a similar intensity as that of normal hu-
man control skin. Unexpectedly, in these LDM-isolated,
type XVII collagen–positive keratinocytes from the
ankle, both of the inherited mutations, 1706delA and
3781CrT, were still present, but a second mutation was
detected on the 3781CrT allele. At position 3782, a
transversion from G to C (3782GrC) had occurred, 1
nt behind the 3781CrT mutation (ﬁg. 3E). This com-
pensatory mutation results in the replacement of the
nonsense mutation at position 1226 to a missense mu-
tation (R1226XrR1226S). Figure 4C shows that the
RNA isolated from the same cells originates mainly from
the corrected allele. The 1706delA allele hardly contrib-
utes, most likely because of degradation by nonsense-
mediated RNA decay, a conserved posttranscriptional
mechanism that prevents the synthesis of truncated pro-
teins that could be deleterious to the cell. Considering
the absence of blister formation after hard rubbing of
the skin on the ankle and the IF staining with the in-
tensity of normal control skin, we conclude that the
produced type XVII collagen with one altered residue is
functional.
A third reversion event was found in the biopsy spec-
imens of the forearm and upper arm. Like the rever-
tant skin of the hand, the LDM-isolated, type XVII col-
lagen–positive keratinocytes of both specimens showed
loss of the maternal 1706delA mutation (ﬁg. 3F). Also,
data from the SNP and microsatellite analysis with
D10S597, on the telomeric side of the COL17A1 gene,
and D10S603, on the centromeric side of COL17A1,
were similar to the data for the hand. However, the SNP
in intron 19 (182214C/T) showed a loss of hetero-
zygosity (table 3) (Gatalica et al. 1997). To conﬁrm our
original data, we reinvestigated the keratinocytes orig-
inally isolated from the hand. New cultures were cyto-
spinned and immunostained, and type XVII collagen–
positive cells were selected by LDM. Results of PCR and
subsequent sequencing were identical to our original
data and again showed heterozygosity of the intron 19
SNP. Thus, in the left forearm and right upper arm of
this female patient, the correction results from another
larger gene conversion of at least 511 bp, including 14
nt of intron 19. The RNA isolated from the type XVII
collagen–positive cells of the upper arm could be at-
tributed solely to the maternal allele (not shown). The
3781CrT mutation of the paternal allele was not pre-
sent, most likely because of nonsense-mediated RNA
decay.
Discussion
This study reveals that, in two compound heterozygous,
unrelated probands, multiple distinct somatic rever-
sions of pathogenic COL17A1 mutations have occurred
that clinically result in discrete patches of functionally
restored skin. In the patients described, both of the in-
herited mutations, paternal as well as maternal, reverted
at least once by different reversion events (ﬁg. 6).
Despite the low number of reversions described in
humans, three cases—one case of FA and two cases of
WAS—were reported in which patients with revertant
mosaicism who were from the same family indepen-
dently developed the same compensatory second-site
mutation (Waisﬁsz et al. 1999; Wada et al. 2003, 2004).
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Figure 5 Depiction of the area of unaffected patches remaining stable over the years. A, Left hand of patient 2 in 1994. The unaffected
skin was outlined with a black marker. B, Left hand in 2005, with the same pigmentation as in 1994, demonstrating the stability of the healthy
skin area. C and D, Forearms of patient 2 in 1994 (C) and 2005 (D), showing the stability of the healthy zones. E and F, Leg of patient 2 in
1994 (E) and 2005 (F). Unaffected skin is located in the middle of the black circle. In panel E, the difference in the erosions situated above
this unaffected area is clearly visible.
Because of the occurrence of the same correcting mu-
tation in the siblings, it was suggested that these second-
site mutations resulted from a speciﬁc molecular mech-
anism, rather than from a randomized process. Waisﬁsz
et al. (1999) showed, in two brothers, the functional
correction of the inherited 1749TrG mutation in the
FANCC gene by the 1748CrT nucleotide change, cre-
ating a cysteine codon (L496C) instead of an arginine
codon (L496R). This transversion was assumed to be
mediated by methylation. In addition, Wada et al. (2003,
2004) implied that DNA polymerase slippage was the
cause of the compensatory deletions in two of their fam-
ilies. In one family, the function of the WAS protein was
restored in two brothers by the same second-site mu-
tation, a deletion of 19 bp that included the original
1305insC mutation in the WASP gene (Wada et al.
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Figure 6 Multiple reversion mutations in patients 1 and 2. In mitosis in a diploid cell after DNA replication and normal segregation,
each daughter cell obtains one chromosome from the father and one from the mother. Homologous chromosomes carry the paternal or maternal
mutation in the COL17A1 gene (black bars). Cells devoid of the protein are depicted in white, and cells with a revertant phenotype are depicted
in gray. The dots in the picture refer to the biopsy sites, and the accompanying drawings show the underlying mechanism of the reverse mutation
of that skin patch. Although the type XVII collagen produced in the cells with a second-site mutation (white bars) was different from the wild-
type protein, the skin displayed a revertant phenotype.
2003). In the other family, DNA polymerase slippage
was also hypothesized to underlie the inherited muta-
tion, a 6-bp sequence insertion, as well as the correction,
the deletion of the same 6-bp sequence (Wada et al.
2004). Our data are fascinatingly different. The mu-
tation 3781CrT, present in both patients, reverted in
two different ways. In patient 1, the reversion was most
likely a true back mutation, whereas, in patient 2, the
second-site mutation 3782GrC resulted in a serine co-
don (R1226S) instead of a stop codon (R1226X). In
contrast to the described siblings with FA and WAS, our
patients are unrelated. Thus, if correction mutations re-
sult from a speciﬁc molecular mechanism, then other
factors also inﬂuence the preference for a certain re-
version mechanism.
In patient 2, gene conversion was demonstrated as
the correcting mechanism for the 1706delA mutation
in three of the four biopsy specimens studied. The spec-
imens of the left forearm and right upper arm, although
located far apart and in separate clusters, had the same
DNA pattern. Therefore, they could have originated ei-
ther from a single early correction event that took place
before lateralization of the embryo or from two inde-
pendent but identical correction events. Since no other
heterozygous SNPs were noticed before exon 18 or be-
tween intron 19 and intron 28, the answer remains elu-
sive. It might be that, in this patient, gene conversion
around the exon 18 mutation is favored as the cor-
recting mechanism because 1706delA is located close to
the COL17A1-CA1 microsatellite in intron 18, con-
sisting of GT repeats. For chromosome 22, an associ-
ation between the recombination frequency and the GT
microsatellite distribution has been demonstrated (Ma-
jewski and Ott 2000).
The ﬁfth type of correction found was the 4463-
1GrA splice-site mutation that corrected the 4424-
5insC mutation. This 3′ splice-site mutation in the rever-
tant keratinocytes of the middle ﬁnger is a new example
of a second-site mutation in humans. Although splice-
site mutations are well known, they have not yet been
described as a mechanism for restoring a frameshift.
The 4463-1GrA at the 3′ end of intron 54 results in a
new hypothetical splice site 1 base downstream that, by
RNA analysis, was demonstrated to be functional. The
analysis of this new hypothetical acceptor splice site of
exon 55 by use of the NetGene2 prediction server was
in line with a conﬁdence value of 0.83.
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Multiple Correcting Mutations in Other Hereditary
Diseases
Recently, a patient with revertant mosaicism of he-
reditary tyrosinemia was described who had multiple
reversion mutations in the FAH gene in different liver
nodules (Bliksrud et al. 2005). This patient was com-
pound heterozygous for a missense mutation in exon 12
(1009GrA; G337S) and a splice-site mutation in intron
12 (IVS125GrA). Three immunopositive liver nodules
were investigated. In one nodule, a compensatory mu-
tation (1061CrA) 6 bp upstream of the inherited splice-
site mutation was detected, whereas, in the other two
nodules, this splice-site mutation reverted to the wild-
type sequence. True mutation reversion of the FAH gene
most often underlies the restoration of the enzymatic
activity. However, in this patient, besides true mutation
reversion, a second-site mutation that restored the 5′
splice site of exon 12 was also identiﬁed. The presence
of multiple correcting mutations in patients with EB and
tyrosinemia type I suggests that, in the future, various
mutations within one patient will be detected for other
genetic diseases also.
Random Mutagenesis versus Directed Mutagenesis
One other patient with revertant nH-JEB with cor-
rection of COL17A1 mutation has been described, al-
though, in this patient, no regions of clinically unaffected
skin were present (Darling et al. 1999). Darling et al.
(1999) found, among three biopsy specimens taken from
nonlesional affected skin, two with focal expression of
type XVII collagen. Keratinocytes independently grown
from a third site also demonstrated restored protein syn-
thesis. LDM analysis of one biopsy specimen revealed
correction of the homozygous 4003delTC deletion by a
frame-restoring insertion of two Gs, 4080insGG, in one
chromosome. The resulting type XVII collagen molecule
was of normal length but had a stretch of 25 altered
amino acids. Thus, at the moment, three patients with
mosaic nH-JEB have been described from among∼3,000
patients with nH-JEB worldwide, established on the ba-
sis of the prevalence of 0.5 per million persons observed
in the United States (Fine et al. 1999). Most likely, the
number of patients with mosaicism is larger than that
reported, since revertant keratinocytes can be present in
affected skin and therefore will often remain unnoticed.
An interesting question, to which the answer is yet un-
clear, is whether these reversions are occurring with a
higher frequency than would be expected by chance.
Recently, in the Arabidopsis plant, it was shown that
the genetic restoration events that took place occurred
with a higher frequency, in the order of a few percent,
than could be explained by random mutagenesis (Lolle
et al. 2005). Those authors postulated that the precise
reversions are the result of a template-directed process
that makes use of an ancestral RNA-sequence cache that
comes from previous generations. Such a mechanism, if
we assume that it would be present in other eukaryotes
as well, would not, however, explain the presence of the
second-site mutations detected in our patients.
Patient 2 has one patch on her left hand that includes
both the middle ﬁnger and the pointing ﬁnger (ﬁg. 5A
and 5B). The reversion event that occurred in these ker-
atinocytes should have taken place before the evolve-
ment of the ﬁngers, in the 8th week of pregnancy. If
we assume that the fetus, at the time of the reversion
event, was not 12.5 cm in length and had a similar skin
constitution as normal human skin, with a keratino-
cyte count of 47,000/mm2 (Bergstresser et al. 1978),
then ∼ keratinocytes were present. With this74.7# 10
amount of cells, given the average human mutation rate
observed by Nachman and Cromwell (2000) of 2.5#
per nucleotide per generation, the chance that such810
a speciﬁc reverse mutation would occur in one of the
fetus’s cells is 0.39 per cell division (Nachman and
Cromwell 2000). This number indicates that such a spe-
ciﬁc mutation could have occurred by chance and that
the mosaic patches could have been the result of random
mutagenesis. Nevertheless, it still leaves open the pos-
sibility that the reverse mutations are the result of a
directed process.
Between different genetic disorders, a large variety in
the frequency of mosaicism exists—for example, it is
present in ∼85% of patients with tyrosinemia type I and
∼20% of patients with Bloom syndrome (German et al.
1977; Demers et al. 2003). The higher frequency of re-
version in tyrosinemia type I, caused by deﬁciency of the
enzyme fumarylacetoacetate hydrolase (FAH), was sug-
gested to arise from the accumulation of the muta-
genic metabolites fumarylacetoacetate and its precursor
maleylacetoacetate in the cell. It is interesting to note
that the extent of FAH mutation reversion, which ranges
from 0.1% to 85% in the studied patients, was inversely
correlated with the clinical severity of the disease (De-
mers et al. 2003). In disorders in which the genetic defect
has an effect on the maintenance of genomic stability,
such as FA and Bloom syndrome, the high reversion
frequencies can be explained by the increased overall
mutation rate. For example, in the autosomal reces-
sive Bloom syndrome, loss-of-function mutations in the
BLM gene, which encodes the RecQ family DNA heli-
case BLM, lead to high rates of exchange between sister
chromatids. Ellis et al. (1995) showed that somatic in-
tragenic recombination in compound heterozygous pa-
tients could generate a functionally wild-type BLM, re-
sulting in cells with a low sister-chromatid exchange rate
and, accordingly, a high percentage of individuals with
mosaicism. In concert with this reversion type is the fact
that patients with a common ancestor very rarely exhibit
mosaicism. Because bilateral cell trafﬁcking between the
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mother and fetus was suggested by a number of studies,
Tanguay and colleagues (Bergeron et al. 2004) decided
to investigate whether, in tyrosinemia type I, such an
event was responsible for the commonly observed liver
mosaicism. However, the corrected liver nodules in their
patients were not of maternal origin, and therefore the
data did not support this hypothesis.
Functional Restoration of the Skin
Our patients demonstrate that reversion of pathogenic
COL17A1 mutations, either to the wild type or to a
slightly altered sequence, may lead to functionally healthy
skin. To obtain this restoration, only one corrected allele
is needed, since nH-JEB is a recessive disease and het-
erozygous carriers display a normal skin phenotype. Fur-
thermore, not all cells need to be reverted, as shown by
the presence of interruptions in the staining of the epi-
dermal basement membrane in the biopsy specimens of
unaffected skin. However, these type XVII collagen–pos-
itive cells have to be present over a sufﬁciently large area.
In patient 1, we found, in one specimen, wild-type ex-
pression of type XVII collagen over ∼0.25 mm2, but this
area was obviously too small.
The earlier that reversion takes place in the embryonic
development in vivo, the more likely that revertant de-
scendant stem cells may ﬁnally spread as larger clusters
and the more beneﬁcial for clinical severity this may be.
Because the correcting mutations were undetectable in
leukocytes derived from mesoderm, all reversion events
in the described patients took place after the develop-
ment of the three-layered embryo in the 2nd week. Al-
though the phylloid mosaic pattern of patient 2 was
bilaterally distributed, the correcting mutations could
have taken place after lateralization of the embryo, be-
cause the revertant patches were not symmetrical and
the reversion events were caused by different mecha-
nisms. The later the reversion occurred during embryo-
genesis, the smaller the patch. It may be that the focal
correction observed in the upper arm of patient 1 and
the focal correction observed by Darling et al. (1999)
reﬂect such late-embryonic events.
The somatic mutations in our patients occurred in
areas of the skin exposed to sunlight—in particular, the
ankle and the extensor surfaces of arms and hands—
and, for this reason, it was suggested that the acquired
somatic mutations could have been environmentally in-
duced early in life. Ultraviolet irradiation may cause
two adjacent pyrimidine residues (C or T) to form a
dimer. If not repaired, mutations in the form of CrT
and CCrTT transitions can be introduced in the DNA
sequence. In our patients, three mutations were intro-
duced: 3781TrC, 3782GrC, and 4463-1GrA. Since
the formation of pyrimidine dimers and (6–4) photo-
products cannot result in a TrC or GrC nucleotide
change, the involvement of ultraviolet irradiation can be
excluded for the 3781TrC and 3782GrC mutations.
In the case of the 4463-1GrAmutation, a possible effect
of ultraviolet irradiation is not ruled out, because the
DNA sequence on the opposite strand contains adjacent
pyrimidine residues.
Stability of the Healthy Skin Patches
Both our patients claimed that their patches of healthy
skin had been there as long as they could remember
and that they had not changed in size. Extensive photo
documentation of patient 2 in 1969, 1994, and 2005
conﬁrmed the stability of the unaffected patches (ﬁg. 5).
Thus, epidermal stem cells with corrected COL17A1
mutation do not spread in favor of their uncorrected
counterparts. Since blistering and subsequent wound
healing frequently occurred on the adjacent type XVII
collagen–negative patches of skin, the expression of type
XVII collagen apparently does not offer a selective ad-
vantage in repopulating stripped epidermis. This may be
the result of hair follicles and sebaceous glands that are
sheltered from subepidermal blistering, and, in this case,
residing mutant stem cells may rapidly cover the wound
area before a reverted stem cell from the periphery can
invade. Our observations seemingly contrast with the
mouse model of epidermolysis bullosa simplex, Dowl-
ing-Meara type (EBS-DM), with an inducible keratin 14
mutation in which wild-type stem cells replaced mutant
keratinocytes in the wound bed (Cao et al. 2001). It also
contradicts the report by Smith et al. (2004) of a rever-
tant mosaic case with a keratin 14 mutation compen-
sated for by a second 1-bp insertion that nulliﬁed the
dominant-negative allele; the patient had experienced
signiﬁcant improvement in the skin-blistering phenotype
from her early teens. It was suggested that revertant mo-
saicism could be responsible for the commonly observed
amelioration with age in EBS-DM, either by multiple
reversions occurring over a relatively short time or by
replacement of mutant cells with revertant cells under
suitable selective pressure. Such pressure is obviously
absent in the mouse model for epidermolytic hyperker-
atosis with mutations in keratin 10, since no spreading
of wild-type cells into the mutated area was observed
(Arin et al. 2001). Here, the mutant stem cells in the
basal layer escape destruction because the epidermolytic
process is suprabasal at the site of keratin 10 expression.
All these results together indicate that the healing over
time of an inherited disease probably depends on the
beneﬁt the stem cells experience from re-expressing the
protein in their competition withmutant stem cells. Since
these mutant stem cells may be located in the hair fol-
licle, interfollicular epidermis, and sebaceous glands, the
spreading of the revertant stem cells probably must also
include destruction of the deeper-located stem cells. In
addition, selective growth advantage was also demon-
strated for FAH-positive hepatocytes in the FAH knock-
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out mouse model of tyrosinemia type I, in which trans-
planted FAH-expressing cells effectively repopulated the
diseased liver, because, in the FAH-deﬁcient cells, the
accumulation of the mutagenic fumarylacetoacetate was
inducing cell-cycle arrest and apoptosis (Overturf et al.
1996; Jorquera and Tanguay 1999). Furthermore, in
WAS, X-linked SCID, and adenosine deaminase deﬁ-
ciency, a selective growth advantage over their protein-
deﬁcient counterparts has also been observed for rever-
tant lymphocytes (Hirschhorn et al. 1996; Stephan et al.
1996; Wada et al. 2003).
In summary, we demonstrate that 2 of 11 Dutch pa-
tients with GABEB (A.M.G.P., unpublished results) have
multiple correcting mutations in COL17A1. Given this
observed high frequency, the occurrence of more than
one reversion event per individual, and the observation
that reversion clusters may be too small to fully restore
function, it is conceivable that reversions have often been
overlooked in other patients. Studying this “natural gene
therapy” will beneﬁt experimental research of gene and
cell therapy and will bring successful therapies for ge-
netic diseases closer to actuality.
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